EUVIMEDEUVIMED entdecken
CrossrefInfokarte

Cardiometabolic index and central adiposity as non-invasive markers of hepatic steatosis and elevated liver stiffness in chronic hepatitis B

Mete Tugcan Ucdal, Guliz Evik

Hepatology Forum · 2026 · 7 (4) · 319-328

DOI: 10.14744/hf.2026.02372 ↗
AbstractBibliografische Angaben

Abstract

Background and Aim: Residual liver disease in chronic hepatitis B (CHB) under long-term antiviral therapy is increasingly metabolic. We assessed whether the cardiometabolic in-dex (CMI), modified CMI (MCMI) and simple anthropometry are associated with hepatic steatosis and elevated liver stiffness. Materials and Methods: In a two-part cross-sectional study, CMI and MCMI were com-pared between inactive hepatitis B virus carriers (n=21) and matched controls (n=27). Separately, 92 nucleos(t)ide-treated CHB patients underwent vibration-controlled tran-sient elastography (VCTE). Significant steatosis was a controlled attenuation parameter (CAP) ≥268 dB/m and elevated liver stiffness a liver stiffness measurement ≥7.0 kPa. No biopsy was performed. Areas under the curve (AUC) were compared by the DeLong test, and cutoff performance was internally validated by bootstrap. Results: CMI and MCMI did not differ between carriers and controls (p>0.6). Significant steatosis occurred in 44 of 91 (48%) and elevated liver stiffness in 48 of 90 (53%). CMI correlated with CAP (rho=0.37, p

Wissen, das zu Ihrer Arbeit passt.

Vom kostenlosen Einstieg über die persönliche Recherche bis zur vollständigen Research Suite.

Tarife ansehen →

Sind alle Verlagsvolltexte enthalten?

Nein. Bibliografische Nachweise, Abstracts und Volltexte sind unterschiedliche Inhalte. Ob ein Volltext verfügbar ist, hängt von der Quelle, Open Access und Ihren vorhandenen Lizenzen ab. Ein EUVIMED-Tarif ersetzt keine zusätzlichen Verlagsrechte.

Tarife ansehen →